Balanced news tone
News Sentiment
1952 sentiment intelligence
Everest Medicines Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
92/100 classification confidence.
directly relevant articles
high-authority source matches
-1.1% over one week, -0.7% over four weeks, trend inactive, and below fair value.
Everest Medicines Grants New Options and Share Awards Under 2026 Scheme
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Everest Medicines Grants New Options and Share Awards Under 2026 Scheme
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 14:42
- Source
- TipRanks
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Market source
Everest Medicines (SEHK:1952) Stock Valuation After New Ophthalmology And Cardiovascular Licensing Deals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- simplywall.st
LENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater China | LENZ Stock News
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 07 Jun 2026 07:00
- Source
- Quiver Quantitative
Everest Medicines
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jun 2026 09:40
- Source
- The Pharma Letter
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- ANTARA News
Everest Medicines Expands Strategic Investment in I-MAB
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 01 Aug 2025 07:00
- Source
- The Manila Times
Everest Medicines raises $200M; Epirium Bio targets $55M Series B
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Jul 2025 07:00
- Source
- Endpoints News
Everest Medicines targets global expansion with proprietary, AI-driven mRNA platform
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Jul 2025 07:00
- Source
- KrASIA
FAST NEWS: Everest Medicines loss widens on drug commercialization
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 28 Aug 2024 07:00
- Source
- thebambooworks.com
Everest makes strong debut in Hong Kong with HK$3.49B IPO
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Oct 2020 07:00
- Source
- BioWorld News
Chinese Biotech Firm Everest Medicines Raises $451 Million in Hong Kong IPO
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Oct 2020 07:00
- Source
- Caixin Global
EVEREST MEDICINES LTD. (1952)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Oct 2020 07:00
- Source
- hkex.com.hk
CBC-incubated Everest Medicines Successfully Lists on HKEX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Oct 2020 07:00
- Source
- PR Newswire